GH Research is focused on finding ultra-rapid and durable remissions in depression with an initial focus on developing its proprietary mebufotenin therapies for the treatment of patients with treatment-resistant-depression, bipolar II disorder with a depressive episode and postpartum depression.
DRUG PROGRAMS TARGET: Major depressive disorder, alcohol use disorder, anxiety and therapy resistant psychiatric disorders.
SUBSTANCE FOCUS: Mebufotenin/5-Meo-DMT.
CLINICAL TRIALS:Yes.
NEWS & PARTNERSHIPS:
2024
The company announced a grant from the European Patent Office for patent No. EP3927337 covering all Mebufotenin (5-MeO-DMT) and Mebufotenin salt products for use in the treatment of major depressive disorder and treatment-resistant depression.
The European Patent Officegranted 2 patents related to mebufotenin. The first, EP4313945, covers the crystalline hydrobromide salt form of the compound and remains in effect until at least 2043. The second, EP3986864, protects a specialized purification method for mebufotenin and is set to expire no earlier than 2040.
2025
The full analysis of its Phase 2b trial for treatment-resistant depression with GH001 confirmed a 73% remission rate at 6 months with infrequent visits and no mandated psychotherapy.
2026
The efficacy of GH001 in treating treatment-resistant depression is largely independent of the number of prior antidepressant treatment failures, a significant departure from the historical pattern of diminishing returns often observed in TRD patients. In this study, remission rates at Day 8 remained consistently high across subgroups, ranging from 53.9% to 63.6% regardless of whether patients had 2, 3, 4 or 5 or more previous treatment failures. These findings, which were published alongside the primary Phase 2b trial results in JAMA Psychiatry, suggest that GH001 could be a highly effective intervention even for patients with extensive and complex treatment histories who typically struggle to find relief with conventional therapies.